Markets in Europe and Asia rose on Friday as positive momentum from the United States obscured downbeat economic numbers from Japan.
Reported by NYTimes.com 2 hours ago.
Wall Street Rebounded Late. Global Investors Followed.
↧
↧
Mesoblast Corporate Review
NEW YORK and MELBOURNE, Australia, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine industry. Two commercial products have already been approved and marketed by the Company’s licensees JCR Pharmaceuticals Co, Ltd. in Japan and Takeda Pharmaceutical Company in Europe. Mesoblast has one product candidate which has successfully completed Phase 3 and with near-term commercial potential in the United States (U.S.), another product candidate having achieved clinical outcomes in line with the U.S. Food and Drug Administration (FDA) guidance for a registrable clinical indication for market authorization, and two additional Phase 3 assets with blockbuster potential.Mesoblast has recently entered into a strategic cardiovascular partnership for China with Tasly Pharmaceutical Group, China’s leading cardiovascular company, and is in advanced and active discussions with a number of potential global commercialization partners to maximize the value proposition of each of our blockbuster cell therapy candidates.
Mesoblast’s royalty income and milestone payments from licensees continues to grow, the Company has sufficient cash to achieve key commercial milestones, and access to additional non-dilutive sources of capital from strategic financial institutions whose extensive due diligence provides further third party validation of the strength of the product portfolio and patent estate.
Below is a summary of the current status of the product portfolio and the developments expected to take place in 2019.
*Substantial Commercialization Opportunities*
Mesoblast’s proprietary immunoselected and culture-expanded allogeneic mesenchymal precursor cells (MPCs) are a homogeneous, well characterized, and highly reproducible cell population that are manufactured to industrial scale for commercial purposes. They express an array of surface receptors that bind pro-inflammatory cytokines and, when placed into a pro-inflammatory microenvironment, release factors that switch off production of these cytokines. Their immunomodulatory mechanism of action makes MPCs uniquely suited to target resistant diseases where inflammation plays a central role.
*Acute Graft Versus Host Disease*, *a Life-threatening Inflammatory Condition*
In Q1 2019, the Company plans to initiate the FDA process of filing a Biologics License Application (BLA) for market authorization of remestemcel-L in the U.S., where there are no approved therapies for steroid-refractory acute Graft Versus Host Disease (aGVHD). Underpinning Mesoblast’s confidence in the U.S. market access plan is the Japan experience, where Mesoblast’s licensee, JCR Pharmaceuticals, markets TEMCELL^®1 HS Inj. for children and adults with aGVHD.
Importantly, TEMCELL has achieved substantial adoption rates in just over 2.5 years, helping inform the view of the product value proposition potential in the U.S. market. With an experienced commercial leadership in place, Mesoblast is establishing a focused sales team that will target the principal U.S. transplant centers, and will be in place on FDA approval to ensure a successful product launch.
*Inflammation Due to Left Ventricular Assist Device Implants in End-stage Heart Failure Patients*
In the first half of 2019, Mesoblast plans to meet with the FDA to discuss a potential approval pathway following the clinically meaningful outcomes of reduction in major gastrointestinal (GI) bleeding and related hospitalizations seen in the U.S. National Institutes of Health (NIH)-sponsored Phase 2 trial of MPC-150-IM (Revascor) in patients with end-stage heart failure and a left ventricular assist device (LVAD). This potentially life-threatening complication is the most common non-surgical complication in LVAD recipients and occurs in up to 40% of patients.
In the 159-patient trial, a single intra-cardiac injection of Revascor resulted in a 76% reduction in major GI bleeding episodes and in 65% reduction in associated hospitalization events. Reduction in GI bleeding and associated hospitalizations were the basis of the Regenerative Medicine Advanced Therapy (RMAT) designation granted in December 2017 by the FDA for use of Revascor in LVAD patients based on concordant data from the earlier 30-patient Pilot Trial. In a subsequent meeting in 2018, the FDA advised Mesoblast that reduction in major GI bleeding in LVAD patients is considered a clinically meaningful outcome by the FDA and an acceptable endpoint for product approval.
In end-stage heart failure, where intra-cardiac inflammation is greatest, putting a foreign object (the LVAD) in contact with the failing left ventricle results in further activation of intra-cardiac inflammation, which exacerbates pre-existing vascular dysfunction in the peripheral organs. The GI blood vessels respond to vascular dysfunction and reduced flow by generation of abnormal thin-walled, leaky capillaries (angiodysplasia). These pre-dispose LVAD patients to massive and life-threatening GI bleeding.
Mesoblast believes that reduction in major GI bleeding episodes by Revascor is due to reduction in intra-cardiac inflammation and the associated vascular dysfunction in peripheral organs, including the GI vessels. If this is correct, this will have significant read-through to the Phase 3 trial in patients with class II/III heart failure where intra-cardiac inflammation and peripheral vascular dysfunction are thought to directly result in recurrent hospitalizations and terminal cardiac events.
*Phase 3 Trial in Moderate to Advanced Chronic Heart Failure**, a Progressive Disease of Cardiac Inflammation*
Mesoblast expects to complete patient recruitment in the Phase 3 trial evaluating Revascor in patients with moderate-to-severe advanced chronic heart failure very shortly. In the U.S. alone, there are more than 1.3 million patients with New York Heart Association (NYHA) class III chronic heart failure who have high rates of morbidity and mortality despite existing therapies. The major unmet medical need in these patients represents a potential multi-billion dollar market opportunity for Mesoblast.
The primary endpoint for this Phase 3 trial is the ability of Revascor to reduce recurrent non-fatal heart failure-related major adverse cardiac events (HF-MACE) in patients with left ventricular dysfunction. The key secondary endpoint is to delay or prevent terminal cardiac events (TCEs), defined as death, left ventricular assist device implantation, or heart transplant.
It is important to note that in the Phase 2 LVAD trial patients with ischemic cause of their heart failure showed the greatest benefits after being treated with Revascor and these patients closely resemble the majority of patients enrolled in the ongoing Phase 3 trial of patients with moderate to advanced heart failure. If the mechanism of action by which Revascor improved GI bleeding is indeed reduction of intra-cardiac inflammation and reversal of impaired functioning of blood vessels (endothelial dysfunction), a known primary cause of morbidity, exercise intolerance, and mortality in heart failure and a proven mechanism of action for many drugs in early heart failure, one would expect to see a reduction in HF-MACE and mortality in this Phase 3 trial.
*Chronic Low Back Pain Due to Inflammatory Degenerative Disc Disease*
In the U.S., the declared opioid public health emergency and significant associated mortality has brought additional attention to Mesoblast’s product candidate, MPC-06-ID, with the Phase 3 trial completing enrollment of 404 patients in 2018. More than half of the prescriptions for opioids are for people seeking relief from chronic low back pain. There is a desperate need for a therapy that can offer both a durable reduction in pain and improvement in function without the risk of opioid addiction.
Underpinning Mesoblast’s confidence that MPC-06-ID may meet this medical need are the Phase 2 data outcomes that supported the ongoing Phase 3 trial which showed that a single intra-discal injection of MPC-06-ID alleviated pain and improved function for up to three years in patients whose symptoms were not adequately treated with current standard of care therapies.
The patient population suffering from chronic low back pain due to intervertebral disease is estimated at more than 3.2 million patients in the U.S. alone. Mesoblast’s objective is to select and secure the ideal strategic partner to maximize the value creation potential inherent in MPC-06-ID.
*Upcoming Milestones*
*Remestemcel-L for Acute Graft Versus Host Disease
* - FDA meetings and BLA filing (Early CY19)
*Revascor for End-Stage Heart Failure
* - Meet with FDA to discuss the clinically meaningful GI bleeding Phase 2 trial data for potential BLA filing (1H CY19)
*Phase 3 Events-driven Trial in Advanced Heart Failure
* - Complete recruitment (Q4 CY18/Q1 CY19)
- Cardiovascular partner Tasly Pharmaceuticals to meet with National Medical Products Administration to discuss the regulatory approval pathway in China (Q1 CY19)
- Establish global partnership
*MPC-06-ID for Chronic Low Back Pain
* - Establish global partnership
*About Mesoblast
*Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). www.mesoblast.com
1. TEMCELL^® HS Inj. is the registered trademark of JCR Pharmaceuticals Co. Ltd.
*Forward-Looking Statements
*This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
For further information, please contact:
Julie Meldrum
Corporate Communications
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Schond Greenway
Investor Relations
T: +1 212 880 2060
E: schond.greenway@mesoblast.com Reported by GlobeNewswire 3 hours ago.
Mesoblast’s royalty income and milestone payments from licensees continues to grow, the Company has sufficient cash to achieve key commercial milestones, and access to additional non-dilutive sources of capital from strategic financial institutions whose extensive due diligence provides further third party validation of the strength of the product portfolio and patent estate.
Below is a summary of the current status of the product portfolio and the developments expected to take place in 2019.
*Substantial Commercialization Opportunities*
Mesoblast’s proprietary immunoselected and culture-expanded allogeneic mesenchymal precursor cells (MPCs) are a homogeneous, well characterized, and highly reproducible cell population that are manufactured to industrial scale for commercial purposes. They express an array of surface receptors that bind pro-inflammatory cytokines and, when placed into a pro-inflammatory microenvironment, release factors that switch off production of these cytokines. Their immunomodulatory mechanism of action makes MPCs uniquely suited to target resistant diseases where inflammation plays a central role.
*Acute Graft Versus Host Disease*, *a Life-threatening Inflammatory Condition*
In Q1 2019, the Company plans to initiate the FDA process of filing a Biologics License Application (BLA) for market authorization of remestemcel-L in the U.S., where there are no approved therapies for steroid-refractory acute Graft Versus Host Disease (aGVHD). Underpinning Mesoblast’s confidence in the U.S. market access plan is the Japan experience, where Mesoblast’s licensee, JCR Pharmaceuticals, markets TEMCELL^®1 HS Inj. for children and adults with aGVHD.
Importantly, TEMCELL has achieved substantial adoption rates in just over 2.5 years, helping inform the view of the product value proposition potential in the U.S. market. With an experienced commercial leadership in place, Mesoblast is establishing a focused sales team that will target the principal U.S. transplant centers, and will be in place on FDA approval to ensure a successful product launch.
*Inflammation Due to Left Ventricular Assist Device Implants in End-stage Heart Failure Patients*
In the first half of 2019, Mesoblast plans to meet with the FDA to discuss a potential approval pathway following the clinically meaningful outcomes of reduction in major gastrointestinal (GI) bleeding and related hospitalizations seen in the U.S. National Institutes of Health (NIH)-sponsored Phase 2 trial of MPC-150-IM (Revascor) in patients with end-stage heart failure and a left ventricular assist device (LVAD). This potentially life-threatening complication is the most common non-surgical complication in LVAD recipients and occurs in up to 40% of patients.
In the 159-patient trial, a single intra-cardiac injection of Revascor resulted in a 76% reduction in major GI bleeding episodes and in 65% reduction in associated hospitalization events. Reduction in GI bleeding and associated hospitalizations were the basis of the Regenerative Medicine Advanced Therapy (RMAT) designation granted in December 2017 by the FDA for use of Revascor in LVAD patients based on concordant data from the earlier 30-patient Pilot Trial. In a subsequent meeting in 2018, the FDA advised Mesoblast that reduction in major GI bleeding in LVAD patients is considered a clinically meaningful outcome by the FDA and an acceptable endpoint for product approval.
In end-stage heart failure, where intra-cardiac inflammation is greatest, putting a foreign object (the LVAD) in contact with the failing left ventricle results in further activation of intra-cardiac inflammation, which exacerbates pre-existing vascular dysfunction in the peripheral organs. The GI blood vessels respond to vascular dysfunction and reduced flow by generation of abnormal thin-walled, leaky capillaries (angiodysplasia). These pre-dispose LVAD patients to massive and life-threatening GI bleeding.
Mesoblast believes that reduction in major GI bleeding episodes by Revascor is due to reduction in intra-cardiac inflammation and the associated vascular dysfunction in peripheral organs, including the GI vessels. If this is correct, this will have significant read-through to the Phase 3 trial in patients with class II/III heart failure where intra-cardiac inflammation and peripheral vascular dysfunction are thought to directly result in recurrent hospitalizations and terminal cardiac events.
*Phase 3 Trial in Moderate to Advanced Chronic Heart Failure**, a Progressive Disease of Cardiac Inflammation*
Mesoblast expects to complete patient recruitment in the Phase 3 trial evaluating Revascor in patients with moderate-to-severe advanced chronic heart failure very shortly. In the U.S. alone, there are more than 1.3 million patients with New York Heart Association (NYHA) class III chronic heart failure who have high rates of morbidity and mortality despite existing therapies. The major unmet medical need in these patients represents a potential multi-billion dollar market opportunity for Mesoblast.
The primary endpoint for this Phase 3 trial is the ability of Revascor to reduce recurrent non-fatal heart failure-related major adverse cardiac events (HF-MACE) in patients with left ventricular dysfunction. The key secondary endpoint is to delay or prevent terminal cardiac events (TCEs), defined as death, left ventricular assist device implantation, or heart transplant.
It is important to note that in the Phase 2 LVAD trial patients with ischemic cause of their heart failure showed the greatest benefits after being treated with Revascor and these patients closely resemble the majority of patients enrolled in the ongoing Phase 3 trial of patients with moderate to advanced heart failure. If the mechanism of action by which Revascor improved GI bleeding is indeed reduction of intra-cardiac inflammation and reversal of impaired functioning of blood vessels (endothelial dysfunction), a known primary cause of morbidity, exercise intolerance, and mortality in heart failure and a proven mechanism of action for many drugs in early heart failure, one would expect to see a reduction in HF-MACE and mortality in this Phase 3 trial.
*Chronic Low Back Pain Due to Inflammatory Degenerative Disc Disease*
In the U.S., the declared opioid public health emergency and significant associated mortality has brought additional attention to Mesoblast’s product candidate, MPC-06-ID, with the Phase 3 trial completing enrollment of 404 patients in 2018. More than half of the prescriptions for opioids are for people seeking relief from chronic low back pain. There is a desperate need for a therapy that can offer both a durable reduction in pain and improvement in function without the risk of opioid addiction.
Underpinning Mesoblast’s confidence that MPC-06-ID may meet this medical need are the Phase 2 data outcomes that supported the ongoing Phase 3 trial which showed that a single intra-discal injection of MPC-06-ID alleviated pain and improved function for up to three years in patients whose symptoms were not adequately treated with current standard of care therapies.
The patient population suffering from chronic low back pain due to intervertebral disease is estimated at more than 3.2 million patients in the U.S. alone. Mesoblast’s objective is to select and secure the ideal strategic partner to maximize the value creation potential inherent in MPC-06-ID.
*Upcoming Milestones*
*Remestemcel-L for Acute Graft Versus Host Disease
* - FDA meetings and BLA filing (Early CY19)
*Revascor for End-Stage Heart Failure
* - Meet with FDA to discuss the clinically meaningful GI bleeding Phase 2 trial data for potential BLA filing (1H CY19)
*Phase 3 Events-driven Trial in Advanced Heart Failure
* - Complete recruitment (Q4 CY18/Q1 CY19)
- Cardiovascular partner Tasly Pharmaceuticals to meet with National Medical Products Administration to discuss the regulatory approval pathway in China (Q1 CY19)
- Establish global partnership
*MPC-06-ID for Chronic Low Back Pain
* - Establish global partnership
*About Mesoblast
*Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). www.mesoblast.com
1. TEMCELL^® HS Inj. is the registered trademark of JCR Pharmaceuticals Co. Ltd.
*Forward-Looking Statements
*This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
For further information, please contact:
Julie Meldrum
Corporate Communications
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Schond Greenway
Investor Relations
T: +1 212 880 2060
E: schond.greenway@mesoblast.com Reported by GlobeNewswire 3 hours ago.
↧
Data on INVL Asset Management UAB issued investment funds units as of December 27, 2018
Vilnius, Lithuania, 2018-12-28 12:27 CET (GLOBE NEWSWIRE) --
Data on INVL Asset Management UAB issued investment funds units is presented in the table as of December 27, 2018
Fund Unit price, EUR Issued units Redeemed units Total number of issued units
INVL Emerging Europe ex Russia TOP20 Subfund 29,8161 279292,7638
INVL Russia TOP20 Subfund 28,0844 5,8659 373,4617 254285,4568
INVL Emerging Europe Bond Subfund 39,2629 611,2641 137,8263 929877,6408
INVL Baltic Fund 34,9714 70,366642 721,232406 189051,963495
INVL Asset Management UAB
Tel. (+370) 700 55 959
www.invl.com Reported by GlobeNewswire 3 hours ago.
Data on INVL Asset Management UAB issued investment funds units is presented in the table as of December 27, 2018
Fund Unit price, EUR Issued units Redeemed units Total number of issued units
INVL Emerging Europe ex Russia TOP20 Subfund 29,8161 279292,7638
INVL Russia TOP20 Subfund 28,0844 5,8659 373,4617 254285,4568
INVL Emerging Europe Bond Subfund 39,2629 611,2641 137,8263 929877,6408
INVL Baltic Fund 34,9714 70,366642 721,232406 189051,963495
INVL Asset Management UAB
Tel. (+370) 700 55 959
www.invl.com Reported by GlobeNewswire 3 hours ago.
↧
Can Ocasio-Cortez’s Left-Wing Populism Counter Trump’s Right-Wing Authoritarianism?
Article by WN.Com Correspondent Dallas Darling It’s hard to deny the range of political approaches which deliberately appeal to the people, and often juxtaposes this same group of people against a so-called elite class, has been on the march. In the U.S. for instance, Sen. Bernie Sanders and Donald Trump dominated the 2016 election. Europe saw populist parties in France, Sweden, Denmark, Norway, Poland, Austria and other countries as well, each one contending for power or already part of the government. Even the Philippines and Latin America witnessed their own naked brands of populism. Namely the kind of right-wing authoritarian populism that’s done for the sake of expediency by those who...
Reported by WorldNews 2 hours ago.
↧
BayWa sells 175 MW solar park 'Don Rodrigo' to MEAG
DGAP-News: BayWa AG / Key word(s): Disposal
28.12.2018 / 12:53
The issuer is solely responsible for the content of this announcement.
--------------------
*BayWa sells 175 MW solar park "Don Rodrigo" to MEAG*
Through its holding company BayWa r.e. GmbH, BayWa AG has sold the solar park "Don Rodrigo" in southern Spain to a group's client of MEAG, asset manager of Munich Re and ERGO. The plant consists of a total of around 500,000 solar panels installed on an area measuring 265 hectares that is located 20 kilometres to the south of Seville. The park's total output amounts to 175 megawatts (MW); it therefore generates roughly the same volume of energy as a conventional peak power plant. The 300 gigawatt hours (GWh) produced annually by the plant will supply the equivalent of around 93,000 Spanish homes with electricity.
"With the scheduled sale of this solar power plant in the fourth quarter of 2018, BayWa r.e. has made an important contribution to the BayWa Group meeting its anticipated overall results for 2018," said a delighted Klaus Josef Lutz, member of the BayWa AG executive board.
Don Rodrigo is currently the largest project realised by BayWa r.e. in the solar area. Over the past few months, up to 10,000 solar panels were installed on site every day.
"What is so special about this project is that we will generate green electricity at market prices without any kind of subsidies, a first in Europe. We are therefore entering a new phase where the energy turnaround is concerned: solar power is now cheaper to produce than conventional power," explains Matthias Taft, BayWa AG's senior energy executive. "The fact that the plant was completed without any delays or complications and its subsequent sale quickly followed are a major success for us. We are planning to generate subsidy-free solar power with similar projects in other southern European countries in the next few years in order to further drive the energy transition throughout Europe."
The power will in future be marketed through a 15-year Power Purchase Agreement (PPA) with the Norwegian energy company Statkraft. The BayWa r.e. service team will also be responsible for the ongoing technical operation of the plant. Following the sale of several solar farms in Great Britain to MEAG in 2014 and 2015, the sale of Don Rodrigo is the third successful collaboration with the asset management firm of Munich Re and ERGO.
BayWa r.e. renewable energy GmbH (BayWa r.e.):
BayWa r.e. renewable energy GmbH is a wholly owned subsidiary of BayWa AG. BayWa r.e. is one of the leading developers, service suppliers, PV wholesalers and energy solution providers in the field of renewable energy. Under the motto "r.e.think energy", the company is active worldwide. As a full-service partner with more than 25 years of experience in the market, BayWa r.e. has already commissioned plants with 2 GW and is responsible for the operational management of more than 5 GW of plant output.
Contact:
Marion Danneboom, BayWa AG, Head of PR/Corporate Communications/Public Affairs,
tel. +49 (0)89/92 22-36 80, Fax +49 (0)89/92 12-36 80,
e-mail: marion.danneboom@baywa.de --------------------
28.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: BayWa AG
Arabellastraße 4
81925 Munich
Germany
Phone: 089/ 9222-3691
Fax: 089/ 9212-3680
E-mail: marion.danneboom@baywa.de
Internet: www.baywa.de
ISIN: DE0005194062, DE0005194005,
WKN: 519406, 519400,
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
End of News DGAP News Service Reported by EQS Group 2 hours ago.
28.12.2018 / 12:53
The issuer is solely responsible for the content of this announcement.
--------------------
*BayWa sells 175 MW solar park "Don Rodrigo" to MEAG*
Through its holding company BayWa r.e. GmbH, BayWa AG has sold the solar park "Don Rodrigo" in southern Spain to a group's client of MEAG, asset manager of Munich Re and ERGO. The plant consists of a total of around 500,000 solar panels installed on an area measuring 265 hectares that is located 20 kilometres to the south of Seville. The park's total output amounts to 175 megawatts (MW); it therefore generates roughly the same volume of energy as a conventional peak power plant. The 300 gigawatt hours (GWh) produced annually by the plant will supply the equivalent of around 93,000 Spanish homes with electricity.
"With the scheduled sale of this solar power plant in the fourth quarter of 2018, BayWa r.e. has made an important contribution to the BayWa Group meeting its anticipated overall results for 2018," said a delighted Klaus Josef Lutz, member of the BayWa AG executive board.
Don Rodrigo is currently the largest project realised by BayWa r.e. in the solar area. Over the past few months, up to 10,000 solar panels were installed on site every day.
"What is so special about this project is that we will generate green electricity at market prices without any kind of subsidies, a first in Europe. We are therefore entering a new phase where the energy turnaround is concerned: solar power is now cheaper to produce than conventional power," explains Matthias Taft, BayWa AG's senior energy executive. "The fact that the plant was completed without any delays or complications and its subsequent sale quickly followed are a major success for us. We are planning to generate subsidy-free solar power with similar projects in other southern European countries in the next few years in order to further drive the energy transition throughout Europe."
The power will in future be marketed through a 15-year Power Purchase Agreement (PPA) with the Norwegian energy company Statkraft. The BayWa r.e. service team will also be responsible for the ongoing technical operation of the plant. Following the sale of several solar farms in Great Britain to MEAG in 2014 and 2015, the sale of Don Rodrigo is the third successful collaboration with the asset management firm of Munich Re and ERGO.
BayWa r.e. renewable energy GmbH (BayWa r.e.):
BayWa r.e. renewable energy GmbH is a wholly owned subsidiary of BayWa AG. BayWa r.e. is one of the leading developers, service suppliers, PV wholesalers and energy solution providers in the field of renewable energy. Under the motto "r.e.think energy", the company is active worldwide. As a full-service partner with more than 25 years of experience in the market, BayWa r.e. has already commissioned plants with 2 GW and is responsible for the operational management of more than 5 GW of plant output.
Contact:
Marion Danneboom, BayWa AG, Head of PR/Corporate Communications/Public Affairs,
tel. +49 (0)89/92 22-36 80, Fax +49 (0)89/92 12-36 80,
e-mail: marion.danneboom@baywa.de --------------------
28.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------
Language: English
Company: BayWa AG
Arabellastraße 4
81925 Munich
Germany
Phone: 089/ 9222-3691
Fax: 089/ 9212-3680
E-mail: marion.danneboom@baywa.de
Internet: www.baywa.de
ISIN: DE0005194062, DE0005194005,
WKN: 519406, 519400,
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
End of News DGAP News Service Reported by EQS Group 2 hours ago.
↧
↧
From Godin to Rabiot the free agents that Premier League clubs can open talks with on January 1
A number of players are out of contract in Europe at the end of the season
Reported by Football.london 2 hours ago.
↧
CLASS ACTION UPDATE for XPO, TDOC and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.*XPO Logistics, Inc. (NYSE: XPO)
Class Period: *February 26, 2014 - December 12, 2018
*Lead Plaintiff Deadline: *February 12, 2019
Join the action: https://www.zlk.com/pslra-1/xpo-logistics-inc-loss-form?wire=3
The lawsuit alleges: XPO Logistics, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) XPO’s highly touted aggressive M&A strategy had yielded only minimal returns to the Company; (ii) XPO was utilizing improper accounting practices to mask its true financial condition, including, inter alia, under-reporting of bad debts and aggressive amortization assumptions; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the *XPO Logistics, Inc.* class action contact jlevi@levikorsinsky.com.
*Teladoc Health, Inc. (NYSE: TDOC)
Class Period: *March 3, 2016 - December 5, 2018
*Lead Plaintiff Deadline: *February 11, 2019
Join the action: https://www.zlk.com/pslra-1/teladoc-health-inc-loss-form?wire=3
The lawsuit alleges that, during the class period, Teladoc Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Executive Vice President and Chief Operating Officer Mark Hirschhorn was engaged in an inappropriate sexual relationship with a subordinate; (ii) Hirschhorn and this subordinate engaged in insider trading to provide themselves with undue benefits; (iii) Hirschhorn caused the subordinate to receive promotions for which she was unqualified, thereby negatively impacting the Company’s operations; (iv) the Company’s enforcement of its own purported employment and trading policies were inadequate to prevent the foregoing conduct; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the *Teladoc Health, Inc.* class action contact jlevi@levikorsinsky.com.
*Allergan plc (NYSE: AGN)
Class Period: *May 9, 2017 - December 19, 2018
*Lead Plaintiff Deadline: *February 19, 2019
Join the action: https://www.zlk.com/pslra-1/allergan-plc-loss-form?wire=3
During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various “pharma and device approvals” and concealed the fact that the Company’s CE Mark for its textured breast implants and tissue expanders was expiring in Europe.
On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du Médicament (“ANSM”), the French regulatory authority, the Company had suspended the sale of these products and that it was withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the company's CE Mark for these products, and the stock price fell drastically following the news.
To learn more about the *Allergan plc* class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com Reported by GlobeNewswire 2 hours ago.
Class Period: *February 26, 2014 - December 12, 2018
*Lead Plaintiff Deadline: *February 12, 2019
Join the action: https://www.zlk.com/pslra-1/xpo-logistics-inc-loss-form?wire=3
The lawsuit alleges: XPO Logistics, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) XPO’s highly touted aggressive M&A strategy had yielded only minimal returns to the Company; (ii) XPO was utilizing improper accounting practices to mask its true financial condition, including, inter alia, under-reporting of bad debts and aggressive amortization assumptions; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the *XPO Logistics, Inc.* class action contact jlevi@levikorsinsky.com.
*Teladoc Health, Inc. (NYSE: TDOC)
Class Period: *March 3, 2016 - December 5, 2018
*Lead Plaintiff Deadline: *February 11, 2019
Join the action: https://www.zlk.com/pslra-1/teladoc-health-inc-loss-form?wire=3
The lawsuit alleges that, during the class period, Teladoc Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Executive Vice President and Chief Operating Officer Mark Hirschhorn was engaged in an inappropriate sexual relationship with a subordinate; (ii) Hirschhorn and this subordinate engaged in insider trading to provide themselves with undue benefits; (iii) Hirschhorn caused the subordinate to receive promotions for which she was unqualified, thereby negatively impacting the Company’s operations; (iv) the Company’s enforcement of its own purported employment and trading policies were inadequate to prevent the foregoing conduct; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the *Teladoc Health, Inc.* class action contact jlevi@levikorsinsky.com.
*Allergan plc (NYSE: AGN)
Class Period: *May 9, 2017 - December 19, 2018
*Lead Plaintiff Deadline: *February 19, 2019
Join the action: https://www.zlk.com/pslra-1/allergan-plc-loss-form?wire=3
During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various “pharma and device approvals” and concealed the fact that the Company’s CE Mark for its textured breast implants and tissue expanders was expiring in Europe.
On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du Médicament (“ANSM”), the French regulatory authority, the Company had suspended the sale of these products and that it was withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the company's CE Mark for these products, and the stock price fell drastically following the news.
To learn more about the *Allergan plc* class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com Reported by GlobeNewswire 2 hours ago.
↧
What's a eurozone? Terms to know as the euro turns 20
FRANKFURT, Germany (AP) — The euro, Europe's shared currency, turns 20 on Tuesday. Here are some key terms to know:— Eurozone: The 19 European Union countries that use the euro. They are: Austria, Belgium, Cyprus, Estonia, Finland,...
Reported by New Zealand Herald 2 hours ago.
↧
Hanwha Q CELLS Announces Shareholder Resolutions Adopted at Annual General Meeting
SEOUL, South Korea, Dec. 28, 2018 /PRNewswire/ -- Hanwha Q CELLS Co., Ltd. ("Hanwha Q CELLS" or the "Company") (NASDAQ: HQCL), a global leading photovoltaic manufacturer of high-performance, high-quality solar modules, today announced the shareholder resolutions adopted at its annual general meeting of shareholders ("AGM") held in Seoul, South Korea on December 28, 2018.Hanwha Q CELLS' shareholders adopted the following resolutions:
· As an ordinary resolution, that Hee Cheul (Charles) Kim, who was elected by the directors of the Company as a director on October 1, 2018, be elected as a director and Chairman of the Company to hold office in accordance with the Articles of Association of the Company for a two-year term with effect from the date of the AGM
· As an ordinary resolution, that Jung Pyo (Jay) Seo, who was nominated for the third term by the directors of the Company as a director on November 20, 2018, be re-elected as a director of the Company to hold office in accordance with the Articles of Association of the Company for a two-year term with effect from the date of the AGM
· As an ordinary resolution, that Young Soon Kim, who was nominated for the second term by the directors of the Company as a director on November 20, 2018, be re-elected as a director of the Company to hold office in accordance with the Articles of Association of the Company for a two-year term with effect from the date of the AGM
· As an ordinary resolution, that Ernst & Young Han Young be appointed as independent auditor of the Company for the financial statements ending December 31, 2018
*About Hanwha Q CELLS *
Hanwha Q CELLS Co., Ltd. (NASDAQ:HQCL) is one of the world's largest and most recognized photovoltaic manufacturers for its high-performance, high-quality solar cells and modules. It is headquartered in Seoul, South Korea (Global Executive HQ) and Thalheim, Germany (Technology & Innovation HQ), with diverse international manufacturing facilities in Malaysia and China. Its domicile is Georgetown, Grand Cayman Islands. Hanwha Q CELLS offers the full spectrum of photovoltaic products, applications and solutions, from modules to kits to systems to large scale solar power plants. Through its growing global business network spanning Europe, North America, Asia, South America, Africa and the Middle East, the Company provides excellent services and long-term partnerships to its customers in the utility, commercial, governmental and residential markets. Hanwha Q CELLS is a flagship company of Hanwha Group, a FORTUNE Global 500 firm and a Top 10 business enterprise in South Korea. For more information, visit: http://www.hanwha-qcells.com/.
*Safe-Harbor Statement*
This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will,""expects,""anticipates,""future,""intends,""plans,""believes,""estimates" and similar statements. Among other things, the quotations from management in this press release and the Hanwha Q CELLS' operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements. Further information regarding these and other risks is included in Hanwha Q CELLS' filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, Hanwha Q CELLS does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content:http://www.prnewswire.com/news-releases/hanwha-q-cells-announces-shareholder-resolutions-adopted-at-annual-general-meeting-300771204.html
Related Links :
http://www.hanwha-qcells.com/ Reported by PR Newswire Asia 2 hours ago.
↧
↧
Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme
First patient treated with Optune^® providing new therapeutic option for an urgent and unmet clinical needSecond product commercialized by Zai Lab in Hong Kong
HONG KONG, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Zai Lab (NASDAQ: ZLAB) today announced the launch of Optune^® (Tumor Treating Fields or TTFields) in Hong Kong for the treatment of glioblastoma multiforme (GBM) with the treatment of its first patient. Hong Kong is the fourth market after the United States, Europe and Japan to have access to this important new medical technology. Optune is the second product, along with the PARP inhibitor ZEJULA^® (niraparib) for the treatment of ovarian cancer, commercialized by Zai Lab in an Asian market.
Optune is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. Zai in-licensed the technology from Novocure in September 2018. Novocure markets Optune in the U.S., Europe, Japan and certain other countries for the treatment of GBM and is in advanced clinical development for multiple solid tumor indications. While Optune is not yet approved for commercialization in China, the technology was included and recommended with Level 1 evidence as a treatment for GBM in China's Glioma Treatment Guideline published in 2016. In December 2018, the national treatment guideline was expanded to include both newly diagnosed and recurrent GBM patients.
Temozolomide (TMZ) is the only therapeutic approved in China for the treatment of newly-diagnosed GBM. Optune will be the second approved therapy. In the pivotal trial conducted by Novocure that was the basis for the product’s regulatory approvals, treatment with Optune in combination with TMZ compared to TMZ alone resulted in a more than doubling of the five-year overall survival (OS) rate. Optune demonstrates a profound compliance response in which median OS increases with the percentage of monthly time using Optune.
“Since our initial launch of ZEJULA in Hong Kong we have been building our commercial infrastructure in preparation of launching Optune into that market,” said William Liang, Chief Commercial Officer of Zai Lab. “We have been working with Novocure to incorporate their operational best practices into our commercial procedures. Successfully launching two products in Hong Kong will also provide us with valuable experience as we prepare to do the same in the larger China market.”
Dr. Samantha Du, founder and CEO of Zai Lab said, “The launch of Optune in Hong Kong to help GBM patients continues our commercialization momentum that started with the approval and launch of ZEJULA in Hong Kong and the recently-announced China National Medical Product Administration’s acceptance of our NDA submission of niraparib as a Category 1 drug for the maintenance treatment of adults recurrent epithelial ovarian, fallopian tube or primary peritoneal ovarian cancer. 2019 is emerging as a transformational year for the company as we continue our commercial progress in Hong Kong, prepare for commercialization in China and continue to grow and advance our differentiated pipeline.”
*About Tumor Treating Fields (Optune*^®)
Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates low intensity, alternating electric fields within a tumor that exert physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death.
*About Zai Lab
*Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, R&D, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.
ZAI LAB CONTACTS:Billy Cho, CFO
+86 137 6151 2501
billy.cho@zailaboratory.com
Media: Nancie Steinberg / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006
nsteinberg@burnsmc.com / rflamm@burnsmc.com
Investors: Jill Steier
Burns McClellan, on behalf of Zai Lab
212-213-0006
jsteier@burnsmc.com Reported by GlobeNewswire 2 hours ago.
HONG KONG, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Zai Lab (NASDAQ: ZLAB) today announced the launch of Optune^® (Tumor Treating Fields or TTFields) in Hong Kong for the treatment of glioblastoma multiforme (GBM) with the treatment of its first patient. Hong Kong is the fourth market after the United States, Europe and Japan to have access to this important new medical technology. Optune is the second product, along with the PARP inhibitor ZEJULA^® (niraparib) for the treatment of ovarian cancer, commercialized by Zai Lab in an Asian market.
Optune is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. Zai in-licensed the technology from Novocure in September 2018. Novocure markets Optune in the U.S., Europe, Japan and certain other countries for the treatment of GBM and is in advanced clinical development for multiple solid tumor indications. While Optune is not yet approved for commercialization in China, the technology was included and recommended with Level 1 evidence as a treatment for GBM in China's Glioma Treatment Guideline published in 2016. In December 2018, the national treatment guideline was expanded to include both newly diagnosed and recurrent GBM patients.
Temozolomide (TMZ) is the only therapeutic approved in China for the treatment of newly-diagnosed GBM. Optune will be the second approved therapy. In the pivotal trial conducted by Novocure that was the basis for the product’s regulatory approvals, treatment with Optune in combination with TMZ compared to TMZ alone resulted in a more than doubling of the five-year overall survival (OS) rate. Optune demonstrates a profound compliance response in which median OS increases with the percentage of monthly time using Optune.
“Since our initial launch of ZEJULA in Hong Kong we have been building our commercial infrastructure in preparation of launching Optune into that market,” said William Liang, Chief Commercial Officer of Zai Lab. “We have been working with Novocure to incorporate their operational best practices into our commercial procedures. Successfully launching two products in Hong Kong will also provide us with valuable experience as we prepare to do the same in the larger China market.”
Dr. Samantha Du, founder and CEO of Zai Lab said, “The launch of Optune in Hong Kong to help GBM patients continues our commercialization momentum that started with the approval and launch of ZEJULA in Hong Kong and the recently-announced China National Medical Product Administration’s acceptance of our NDA submission of niraparib as a Category 1 drug for the maintenance treatment of adults recurrent epithelial ovarian, fallopian tube or primary peritoneal ovarian cancer. 2019 is emerging as a transformational year for the company as we continue our commercial progress in Hong Kong, prepare for commercialization in China and continue to grow and advance our differentiated pipeline.”
*About Tumor Treating Fields (Optune*^®)
Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates low intensity, alternating electric fields within a tumor that exert physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death.
*About Zai Lab
*Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, R&D, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.
ZAI LAB CONTACTS:Billy Cho, CFO
+86 137 6151 2501
billy.cho@zailaboratory.com
Media: Nancie Steinberg / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006
nsteinberg@burnsmc.com / rflamm@burnsmc.com
Investors: Jill Steier
Burns McClellan, on behalf of Zai Lab
212-213-0006
jsteier@burnsmc.com Reported by GlobeNewswire 2 hours ago.
↧
Manchester United to spend HUGE £90m on Sergej Milinkovic-Savic, Chelsea to re-sign Hazard
The latest transfer news and rumours from the Premier League and Europe
Reported by Plymouth Herald 1 hour ago.
↧
Vestas wins 99 MW EPC order in Ukraine
*News release from **Vestas Northern and Central Europe*
Hamburg, 28 December
Vestas has received a 99 MW Engineering, Procurement and Construction (EPC) order from DTEK Renewables for the Orlovka wind project in the Zaporizhia region, Ukraine.
The order includes 4 MW platform turbines delivered in 3.8 MW Power Optimised Mode as well as a 20-year Active Output Management 5000 (AOM 5000) service contract. Deliveries are expected to begin in the first quarter of 2019, while commissioning is planned for the fourth quarter of 2019.
“With this order, Vestas reinforces its leading role in Ukraine’s renewable energy market and continues to support the country’s renewable ambitions. We are pleased to be awarded yet another order from DTEK, Ukraine’s largest energy company“, says Nils de Baar, President of Vestas Northern & Central Europe.
*For more information, please contact:*
Kresten Ørnbjerg
Tel: +45 52 26 12 81
Email: kroch@vestas.com
*About Vestas*
Vestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service wind turbines across the globe, and with 97 GW of wind turbines in 79 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled 83 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 24,400 employees are bringing the world sustainable energy solutions to power a bright future.
We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels:
· www.twitter.com/vestas
· www.linkedin.com/company/vestas
· www.facebook.com/vestas
· www.instagram.com/vestas
· www.youtube.com/vestas
*Attachment*
· 181228_nr_uk_nce Reported by GlobeNewswire 1 hour ago.
Hamburg, 28 December
Vestas has received a 99 MW Engineering, Procurement and Construction (EPC) order from DTEK Renewables for the Orlovka wind project in the Zaporizhia region, Ukraine.
The order includes 4 MW platform turbines delivered in 3.8 MW Power Optimised Mode as well as a 20-year Active Output Management 5000 (AOM 5000) service contract. Deliveries are expected to begin in the first quarter of 2019, while commissioning is planned for the fourth quarter of 2019.
“With this order, Vestas reinforces its leading role in Ukraine’s renewable energy market and continues to support the country’s renewable ambitions. We are pleased to be awarded yet another order from DTEK, Ukraine’s largest energy company“, says Nils de Baar, President of Vestas Northern & Central Europe.
*For more information, please contact:*
Kresten Ørnbjerg
Tel: +45 52 26 12 81
Email: kroch@vestas.com
*About Vestas*
Vestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service wind turbines across the globe, and with 97 GW of wind turbines in 79 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled 83 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 24,400 employees are bringing the world sustainable energy solutions to power a bright future.
We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels:
· www.twitter.com/vestas
· www.linkedin.com/company/vestas
· www.facebook.com/vestas
· www.instagram.com/vestas
· www.youtube.com/vestas
*Attachment*
· 181228_nr_uk_nce Reported by GlobeNewswire 1 hour ago.
↧
AGF Announces Final Distributions for AGFiQ ETFs for 2018
TORONTO, Dec. 28, 2018 (GLOBE NEWSWIRE) -- AGF Investments Inc. (AGF) today announced the final December 2018 cash distributions and annual 2018 reinvested capital gains distributions for the AGFiQ ETFs listed on the Toronto Stock Exchange or NEO Exchange.Unitholders of record of an AGFiQ ETF on December 31, 2018 will receive (i) the actual 2018 reinvested capital gains distributions payable in respect of that AGFiQ ETF on December 31, 2018; and (ii) the actual December 2018 cash distributions payable in respect of that AGFiQ ETF on January 4, 2019. The actual taxable amounts for 2018, including the tax characteristics, will be reported in early 2019.
The annual reinvested capital gains distributions generally represent realized capital gains within the AGFiQ ETFs and will not be paid in cash, but will be reinvested in the form of a notional distribution and reported as taxable. A notional distribution is when the units from a reinvested distribution are immediately consolidated with the units held prior to the distribution. The number of units held after the distribution is therefore identical to the number of units held before the distribution. The unitholder’s adjusted cost base for the respective AGFiQ ETF may increase.
Details regarding the final “per unit” cash and reinvested capital gains distribution amounts are as follows:
*Fund Name* *Fund Ticker* *Exchange* *Final Cash Distribution Per Unit ($)* *Final Annual Reinvested Capital Gains Distribution Per Unit ($)*
AGFiQ Enhanced Core Canadian Equity ETF QCD Toronto Stock Exchange 0.457091 0.087597
AGFiQ Enhanced Core US Equity ETF QUS Toronto Stock Exchange 0.348477 0.989165
AGFiQ Enhanced Core International Equity ETF QIE Toronto Stock Exchange 1.369738 0.021463
AGFiQ Enhanced Core Emerging Markets Equity ETF QEM Toronto Stock Exchange 0.742155 0.382352
AGFiQ Enhanced Global Infrastructure ETF QIF NEO Exchange 0.202969 -
AGFiQ Enhanced Global ESG Factors ETF QEF NEO Exchange 0.258653 -
AGFiQ Enhanced Core Global Multi-Sector Bond ETF QGB NEO Exchange 0.181857 0.144748
AGFiQ Global Equity Rotation ETF QGL Toronto Stock Exchange 0.556875 0.888480
AGFiQ MultiAsset Allocation ETF QMA Toronto Stock Exchange 0.478578 1.309836
AGFiQ MultiAsset Income Allocation ETF QMY Toronto Stock Exchange 0.289840 0.321107
Further information about the AGFiQ ETFs can be found at AGFiQ.com.
This information is not intended to provide legal, accounting, tax, investment, financial, or other advice, and should not be relied upon for providing such advice. Commissions, management fees and expenses all may be associated with an investment in exchange-traded funds (ETFs). Please read the prospectus or relevant ETF Facts before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Units of ETFs are bought and sold at market price on a stock exchange and brokerage commissions will reduce returns.
*ABOUT AGF MANAGEMENT LIMITED*
Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. AGF brings a disciplined approach to delivering excellence in investment management through its fundamental, quantitative, alternative and high-net-worth businesses focused on providing an exceptional client experience. AGF’s suite of investment solutions extends globally to a wide range of clients, from financial advisors and individual investors to institutional investors including pension plans, corporate plans, sovereign wealth funds and endowments and foundations.
AGF has investment operations and client servicing teams on the ground in North America, Europe and Asia. With nearly $38 billion in total assets under management, AGF serves more than one million investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.
*Media Contact*
Amanda Marchment
Director, Corporate Communications
416-865-4160
amanda.marchment@agf.com Reported by GlobeNewswire 1 hour ago.
The annual reinvested capital gains distributions generally represent realized capital gains within the AGFiQ ETFs and will not be paid in cash, but will be reinvested in the form of a notional distribution and reported as taxable. A notional distribution is when the units from a reinvested distribution are immediately consolidated with the units held prior to the distribution. The number of units held after the distribution is therefore identical to the number of units held before the distribution. The unitholder’s adjusted cost base for the respective AGFiQ ETF may increase.
Details regarding the final “per unit” cash and reinvested capital gains distribution amounts are as follows:
*Fund Name* *Fund Ticker* *Exchange* *Final Cash Distribution Per Unit ($)* *Final Annual Reinvested Capital Gains Distribution Per Unit ($)*
AGFiQ Enhanced Core Canadian Equity ETF QCD Toronto Stock Exchange 0.457091 0.087597
AGFiQ Enhanced Core US Equity ETF QUS Toronto Stock Exchange 0.348477 0.989165
AGFiQ Enhanced Core International Equity ETF QIE Toronto Stock Exchange 1.369738 0.021463
AGFiQ Enhanced Core Emerging Markets Equity ETF QEM Toronto Stock Exchange 0.742155 0.382352
AGFiQ Enhanced Global Infrastructure ETF QIF NEO Exchange 0.202969 -
AGFiQ Enhanced Global ESG Factors ETF QEF NEO Exchange 0.258653 -
AGFiQ Enhanced Core Global Multi-Sector Bond ETF QGB NEO Exchange 0.181857 0.144748
AGFiQ Global Equity Rotation ETF QGL Toronto Stock Exchange 0.556875 0.888480
AGFiQ MultiAsset Allocation ETF QMA Toronto Stock Exchange 0.478578 1.309836
AGFiQ MultiAsset Income Allocation ETF QMY Toronto Stock Exchange 0.289840 0.321107
Further information about the AGFiQ ETFs can be found at AGFiQ.com.
This information is not intended to provide legal, accounting, tax, investment, financial, or other advice, and should not be relied upon for providing such advice. Commissions, management fees and expenses all may be associated with an investment in exchange-traded funds (ETFs). Please read the prospectus or relevant ETF Facts before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Units of ETFs are bought and sold at market price on a stock exchange and brokerage commissions will reduce returns.
*ABOUT AGF MANAGEMENT LIMITED*
Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. AGF brings a disciplined approach to delivering excellence in investment management through its fundamental, quantitative, alternative and high-net-worth businesses focused on providing an exceptional client experience. AGF’s suite of investment solutions extends globally to a wide range of clients, from financial advisors and individual investors to institutional investors including pension plans, corporate plans, sovereign wealth funds and endowments and foundations.
AGF has investment operations and client servicing teams on the ground in North America, Europe and Asia. With nearly $38 billion in total assets under management, AGF serves more than one million investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.
*Media Contact*
Amanda Marchment
Director, Corporate Communications
416-865-4160
amanda.marchment@agf.com Reported by GlobeNewswire 1 hour ago.
↧
↧
Liverpool and Manchester City to fight for £45m signing of Porto's Eder Militao
The latest transfer news and rumours from the Premier League and Europe
Reported by Tiverton Mid Devon Gazette 1 hour ago.
↧
Vestas receives 88 MW order in Poland from recent auction
*News release from **Vestas Northern and Central Europe*
Hamburg, 28 DecemberVestas has received an 88 MW order from the Polish state utility PGE for the 22 MW Karnice II and 66 MW Starza Rybice projects that were amongst the winning wind projects at the Polish energy auction held in November 2018.
The two projects will feature 10 V110-2.2 MW and 33 V100-2.0 MW respectively as well as a 2-year Active Output Management 4000 (AOM 4000) service contract including the VestasOnline® Business SCADA solution.
“We are pleased that Poland is back as an onshore wind market with the recent energy neutral auction being dominated by wind projects at very competitive prices. The auction win underlines Vestas’ ability to deliver clean, low-cost wind energy that will ensure many economic benefits to the local community”, says Nils de Baar, President of Vestas Northern and Central Europe.
Deliveries are expected to begin in third quarter of 2019, while commissioning is planned for fourth quarter of 2019.
*For more information, please contact:*
Kresten Ørnbjerg
Tel: +45 52 26 12 81
Email: kroch@vestas.com
*About Vestas*
Vestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service wind turbines across the globe, and with 97 GW of wind turbines in 79 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled 83 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 24,400 employees are bringing the world sustainable energy solutions to power a bright future.
We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels:
· www.twitter.com/vestas
· www.linkedin.com/company/vestas
· www.facebook.com/vestas
· www.instagram.com/vestas
· www.youtube.com/vestas
*Attachment*
· 181228_nr_uk_nce_2 Reported by GlobeNewswire 54 minutes ago.
Hamburg, 28 DecemberVestas has received an 88 MW order from the Polish state utility PGE for the 22 MW Karnice II and 66 MW Starza Rybice projects that were amongst the winning wind projects at the Polish energy auction held in November 2018.
The two projects will feature 10 V110-2.2 MW and 33 V100-2.0 MW respectively as well as a 2-year Active Output Management 4000 (AOM 4000) service contract including the VestasOnline® Business SCADA solution.
“We are pleased that Poland is back as an onshore wind market with the recent energy neutral auction being dominated by wind projects at very competitive prices. The auction win underlines Vestas’ ability to deliver clean, low-cost wind energy that will ensure many economic benefits to the local community”, says Nils de Baar, President of Vestas Northern and Central Europe.
Deliveries are expected to begin in third quarter of 2019, while commissioning is planned for fourth quarter of 2019.
*For more information, please contact:*
Kresten Ørnbjerg
Tel: +45 52 26 12 81
Email: kroch@vestas.com
*About Vestas*
Vestas is the energy industry’s global partner on sustainable energy solutions. We design, manufacture, install, and service wind turbines across the globe, and with 97 GW of wind turbines in 79 countries, we have installed more wind power than anyone else. Through our industry-leading smart data capabilities and unparalleled 83 GW of wind turbines under service, we use data to interpret, forecast, and exploit wind resources and deliver best-in-class wind power solutions. Together with our customers, Vestas’ more than 24,400 employees are bringing the world sustainable energy solutions to power a bright future.
We invite you to learn more about Vestas by visiting our website at www.vestas.com and following us on our social media channels:
· www.twitter.com/vestas
· www.linkedin.com/company/vestas
· www.facebook.com/vestas
· www.instagram.com/vestas
· www.youtube.com/vestas
*Attachment*
· 181228_nr_uk_nce_2 Reported by GlobeNewswire 54 minutes ago.
↧
Siyata Mobile Provides Year End Corporate Update
MONTRÉAL, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (the "Company" or "Siyata") (TSX-V:SIM / OTCQX:SYATF) is pleased to provide an update on the Company’s progress of 2018 initiatives and provide insight for 2019.Marc Seelenfreund, CEO and Chairman of Siyata Mobile, commented, “We started 2018 with specific targets in mind. Despite the lengthy process that comes with cellular device launches with Tier 1 operators, we have kept moving in the right direction and reached a few critical milestones. We believe that 2019 will be a great year for Siyata with significant revenue and margin growth as we roll out the UV350 in the United States, Canada and other international markets.”
The market demand for 3G in-vehicle communications continued to drive sales through 2018, with sizeable purchase orders coming from various industries while transitioning to the Company’s 4G product portfolio which started gaining traction in our existing markets.
*Recognition as a TSX Venture Top 50 Company*
Siyata started the year strong with the TSX Venture recognizing Siyata for the Company’s tremendous growth over 2017 and active trading in the market. Strong trading volume continued with over 45,142,795 shares traded to date in 2018.
*Purchase Orders*
Multiple large-scale purchase orders were received by Siyata this year, representing the market demand for Push-to-Talk Over Cellular communication systems. Siyata's UV350, CP250 and Rugged Smartphone devices were ordered from a variety of industries including, a First Responder network; the hospitality industry; a public transportation company; a multinational silicon chipset company; an airport logistics company; and a global two-way radio vendor and others.
*Uniden® UV350 Launch with Tier 1 Canadian Operator*
After trialing and testing Siyata’s Uniden UV350, Siyata launched the world’s first and only multi-purpose 4G/LTE commercial vehicle smartphone with a Tier 1 Canadian operator. The dedicated 4G/LTE in-vehicle smartphone is designed for safer, smarter and more advanced instant communication in commercial fleets and vehicles. Customer trials have commenced, and the Company expects its first order shortly.
According to Statistics Canada, there were a total of 1.16 million vehicles which fall into the commercial vehicle category, representing a total addressable market in Canada of ~$1 billion.
*Siyata UV350 Launch in Israel with Global Two Way Radio Vendor*
Siyata announced a partnership with a global land mobile radio vendor in Israel, where they will offer the UV350 to their enterprise customers bundled with their powerful WAVE PTT platform. As a result, the Companies have already won prestigious tenders in Israel and continue to win business.
*Supply Agreement with Tier 1 U.S Operator*
Siyata recently completed a supply agreement with a leading Tier 1 cellular operator in the United States. This agreement is a prerequisite to launching the Uniden® UV350 with this operator in the U.S. and covers all the terms and conditions related to the distribution, pricing, logistics, warranty, legal terms and more.
*Additional Partnerships*
Siyata entered into sales partnerships with key partners including Ingram Micro in the US, SETMA in France, Logic Wireless in New Zealand, Aina and Alcan in Canada and others. These partnerships will be key for 2019 sales and will assist Siyata in ramping up its sales across multiple markets.
*2019 And Beyond*
Siyata continues towards launching its Uniden® UV350 smartphone with two U.S Tier 1 operators who have distribution and sales channels many times larger than the existing sales channels of the Company.
With around 9.7 million commercial vehicles and over 3.5 million first responder vehicles that have yet transitioned to cellular based technology, the Company sees the U.S market as its largest opportunity with a total addressable market well over $11 billion. These tier 1 cellular operators have a keen interest in launching the UV350 as it allows for new SIM card activations and increased ARPU from existing customers while targeting new customers with a unique, dedicated, multi-purpose in-vehicle smartphone.
Siyata’s seven years’ experience of perfecting in-vehicle cellular based technology, industry know-how, vehicle installations, software integration with various PTT solutions and carrier integration have well positioned the Company to be launching with these U.S. operators. The Company believes the final network approval will take place in early 2019.
With the recently completed financing, the Company is well financed for this U.S rollout in 2019 and expects strong sales and margin growth in 2019.
*Grant of Options*
The Company additionally announces it has granted 2,210,00 options, expiring December 24, 2023 and vesting quarterly over three years, exercisable to acquire one share in the capital of the Company at $0.50 per share to certain directors, officers, employees and consultants of the Company. A total of 50% of the Director Options will vest immediately, with the remainder to vest on a quarterly basis over a 15 month period in five (5) equal tranches with the first tranche vesting on March 24, 2019.
*About Siyata*
A TSX Venture Top 50 Company, Siyata Mobile Inc. is a leading global developer and provider of cellular communications systems for enterprise customers, specializing in connected vehicle products for professional fleets, marketed under the Uniden® Cellular brand. Since developing the world’s first 3G connected vehicle device, Siyata has been a pioneer in the industry, launching the world’s first 4G LTE all-in-one fleet communications device in 2017. Incorporating voice, push-to-talk over cellular, data, and fleet management solutions into a single device, the company aims to become the connected vehicle communications device of choice for commercial vehicles and fleets around the world.
Siyata also offers rugged phones for industrial users and signal boosters for homes, buildings, and fleets with poor cell coverage. Siyata’s customers include cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia, and the Middle East.
Visit www.siyatamobile.com and http://www.unidencellular.com/ to learn more.
On Behalf of the Board of Directors of:
*SIYATA MOBILE INC.*
Marc Seelenfreund
CEO and Chairman
*Investor Relations:*
Arlen Hansen
Kin Communications
1-866-684-6730
SIM@kincommunications.com
*Sales Department:*
Glenn Kennedy, VP Sales
Siyata Mobile Inc.
416-892-1823
glenn_kennedy@siyatamobile.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. Reported by GlobeNewswire 43 minutes ago.
The market demand for 3G in-vehicle communications continued to drive sales through 2018, with sizeable purchase orders coming from various industries while transitioning to the Company’s 4G product portfolio which started gaining traction in our existing markets.
*Recognition as a TSX Venture Top 50 Company*
Siyata started the year strong with the TSX Venture recognizing Siyata for the Company’s tremendous growth over 2017 and active trading in the market. Strong trading volume continued with over 45,142,795 shares traded to date in 2018.
*Purchase Orders*
Multiple large-scale purchase orders were received by Siyata this year, representing the market demand for Push-to-Talk Over Cellular communication systems. Siyata's UV350, CP250 and Rugged Smartphone devices were ordered from a variety of industries including, a First Responder network; the hospitality industry; a public transportation company; a multinational silicon chipset company; an airport logistics company; and a global two-way radio vendor and others.
*Uniden® UV350 Launch with Tier 1 Canadian Operator*
After trialing and testing Siyata’s Uniden UV350, Siyata launched the world’s first and only multi-purpose 4G/LTE commercial vehicle smartphone with a Tier 1 Canadian operator. The dedicated 4G/LTE in-vehicle smartphone is designed for safer, smarter and more advanced instant communication in commercial fleets and vehicles. Customer trials have commenced, and the Company expects its first order shortly.
According to Statistics Canada, there were a total of 1.16 million vehicles which fall into the commercial vehicle category, representing a total addressable market in Canada of ~$1 billion.
*Siyata UV350 Launch in Israel with Global Two Way Radio Vendor*
Siyata announced a partnership with a global land mobile radio vendor in Israel, where they will offer the UV350 to their enterprise customers bundled with their powerful WAVE PTT platform. As a result, the Companies have already won prestigious tenders in Israel and continue to win business.
*Supply Agreement with Tier 1 U.S Operator*
Siyata recently completed a supply agreement with a leading Tier 1 cellular operator in the United States. This agreement is a prerequisite to launching the Uniden® UV350 with this operator in the U.S. and covers all the terms and conditions related to the distribution, pricing, logistics, warranty, legal terms and more.
*Additional Partnerships*
Siyata entered into sales partnerships with key partners including Ingram Micro in the US, SETMA in France, Logic Wireless in New Zealand, Aina and Alcan in Canada and others. These partnerships will be key for 2019 sales and will assist Siyata in ramping up its sales across multiple markets.
*2019 And Beyond*
Siyata continues towards launching its Uniden® UV350 smartphone with two U.S Tier 1 operators who have distribution and sales channels many times larger than the existing sales channels of the Company.
With around 9.7 million commercial vehicles and over 3.5 million first responder vehicles that have yet transitioned to cellular based technology, the Company sees the U.S market as its largest opportunity with a total addressable market well over $11 billion. These tier 1 cellular operators have a keen interest in launching the UV350 as it allows for new SIM card activations and increased ARPU from existing customers while targeting new customers with a unique, dedicated, multi-purpose in-vehicle smartphone.
Siyata’s seven years’ experience of perfecting in-vehicle cellular based technology, industry know-how, vehicle installations, software integration with various PTT solutions and carrier integration have well positioned the Company to be launching with these U.S. operators. The Company believes the final network approval will take place in early 2019.
With the recently completed financing, the Company is well financed for this U.S rollout in 2019 and expects strong sales and margin growth in 2019.
*Grant of Options*
The Company additionally announces it has granted 2,210,00 options, expiring December 24, 2023 and vesting quarterly over three years, exercisable to acquire one share in the capital of the Company at $0.50 per share to certain directors, officers, employees and consultants of the Company. A total of 50% of the Director Options will vest immediately, with the remainder to vest on a quarterly basis over a 15 month period in five (5) equal tranches with the first tranche vesting on March 24, 2019.
*About Siyata*
A TSX Venture Top 50 Company, Siyata Mobile Inc. is a leading global developer and provider of cellular communications systems for enterprise customers, specializing in connected vehicle products for professional fleets, marketed under the Uniden® Cellular brand. Since developing the world’s first 3G connected vehicle device, Siyata has been a pioneer in the industry, launching the world’s first 4G LTE all-in-one fleet communications device in 2017. Incorporating voice, push-to-talk over cellular, data, and fleet management solutions into a single device, the company aims to become the connected vehicle communications device of choice for commercial vehicles and fleets around the world.
Siyata also offers rugged phones for industrial users and signal boosters for homes, buildings, and fleets with poor cell coverage. Siyata’s customers include cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia, and the Middle East.
Visit www.siyatamobile.com and http://www.unidencellular.com/ to learn more.
On Behalf of the Board of Directors of:
*SIYATA MOBILE INC.*
Marc Seelenfreund
CEO and Chairman
*Investor Relations:*
Arlen Hansen
Kin Communications
1-866-684-6730
SIM@kincommunications.com
*Sales Department:*
Glenn Kennedy, VP Sales
Siyata Mobile Inc.
416-892-1823
glenn_kennedy@siyatamobile.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. Reported by GlobeNewswire 43 minutes ago.
↧
New Accounting Ref Date
*WisdomTree Issuer plc – Daily Fund Prices * *27-December-18*
* * * *
Fund Dealing Date ISIN Code Shares Base Net Assets NAV/Share
in Issue Currency
WisdomTree Artificial Intelligence UCITS ETF - USD Acc 27/12/2018 IE00BDVPNG13 40000 USD 910,745.18 22.7686
WisdomTree AT1 CoCo Bond UCITS ETF – USD 27/12/2018 IE00BZ0XVF52 290054 USD 26,907,309.00 92.7666
WisdomTree AT1 CoCo Bond UCITS ETF – EUR Hedged 27/12/2018 IE00BFNNN236 20828 EUR 2,011,849.41 96.5935
WisdomTree AT1 CoCo Bond UCITS ETF – GBP Hedged 27/12/2018 IE00BFNNN459 20740 GBP 2,013,541.98 97.085
WisdomTree AT1 CoCo Bond UCITS ETF – USD Acc 27/12/2018 IE00BZ0XVG69 7000 USD 652,259.97 93.18
WisdomTree AT1 CoCo Bond UCITS ETF – USD Hedged 27/12/2018 IE00BFNNN012 20962 USD 2,047,864.36 97.6941
WisdomTree CBOE S&P 500 PutWrite UCITS ETF - USD Acc 27/12/2018 IE00BD49R243 1630000 USD 74,633,063.57 45.7872
WisdomTree Emerging Asia Equity Income UCITS ETF 27/12/2018 IE00BYPGT035 1125000 USD 11,765,433.70 10.4582
WisdomTree Emerging Markets Equity Income UCITS ETF 27/12/2018 IE00BQQ3Q067 1792097 USD 25,939,217.53 14.4742
WisdomTree Emerging Markets Equity Income UCITS ETF Acc 27/12/2018 IE00BDF12W49 108242 USD 1,980,193.33 18.2941
WisdomTree Emerging Markets Small Cap Dividend UCITS ETF 27/12/2018 IE00BQZJBM26 1500000 USD 23,493,917.43 15.6626
WisdomTree Enhanced Commodity UCITS ETF – EUR Hedged Acc 27/12/2018 IE00BG88WG77 25000 EUR 231,753.89 9.2702
WisdomTree Enhanced Commodity UCITS ETF – GBP Hedged Acc 27/12/2018 IE00BG88WH84 1425000 GBP 13,266,277.11 9.3097
WisdomTree Enhanced Commodity UCITS ETF - USD 27/12/2018 IE00BZ1GHD37 475000 USD 4,670,919.51 9.8335
WisdomTree Enhanced Commodity UCITS ETF - USD Acc 27/12/2018 IE00BYMLZY74 22575000 USD 222,961,539.52 9.8765
WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR 27/12/2018 IE00BD49R912 30000 EUR 1,495,464.10 49.8488
WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR Acc 27/12/2018 IE00BD49RB39 30000 EUR 1,495,465.38 49.8488
WisdomTree EUR Government Bond Enhanced Yield UCITS ETF 27/12/2018 IE00BD49RJ15 30000 EUR 1,508,868.96 50.2956
WisdomTree EUR Government Bond Enhanced Yield UCITS ETF – EUR Acc 27/12/2018 IE00BD49RK20 30000 EUR 1,508,869.58 50.2957
WisdomTree Europe Equity Income UCITS ETF 27/12/2018 IE00BQZJBX31 3632471 EUR 41,807,175.13 11.5093
WisdomTree Europe Equity Income UCITS ETF Acc 27/12/2018 IE00BDF16007 40998 EUR 538,820.98 13.1426
WisdomTree Europe Equity UCITS ETF - CHF Hedged Acc 27/12/2018 IE00BYQCZT11 17096 CHF 246,471.31 14.4169
WisdomTree Europe Equity UCITS ETF - EUR Acc 27/12/2018 IE00BYQCZX56 540306 EUR 7,913,980.65 14.6472
WisdomTree Europe Equity UCITS ETF - GBP Hedged 27/12/2018 IE00BYQCZQ89 342454 GBP 3,294,376.42 9.6199
WisdomTree Europe Equity UCITS ETF - USD Hedged 27/12/2018 IE00BVXBH163 2668352 USD 40,749,156.80 15.2713
WisdomTree Europe Equity UCITS ETF - USD Hedged Acc 27/12/2018 IE00BYQCZP72 4249312 USD 73,160,282.15 17.217
WisdomTree Europe Small Cap Dividend UCITS ETF 27/12/2018 IE00BQZJC527 3230006 EUR 45,877,317.99 14.2035
WisdomTree Europe Small Cap Dividend UCITS ETF Acc 27/12/2018 IE00BDF16114 702168 EUR 8,653,092.61 12.3234
WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR 27/12/2018 IE00BZ56SY76 333881 EUR 4,193,658.43 12.5603
WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR Acc 27/12/2018 IE00BZ56TQ67 938013 EUR 13,016,350.80 13.8765
WisdomTree Germany Equity UCITS ETF - CHF Hedged Acc 27/12/2018 IE00BYQCZ914 45884 CHF 714,785.43 15.5781
WisdomTree Germany Equity UCITS ETF - EUR Acc 27/12/2018 IE00BYQCZC44 251123 EUR 3,484,112.35 13.8741
WisdomTree Germany Equity UCITS ETF - GBP Hedged 27/12/2018 IE00BVXBGY20 507894 GBP 4,417,130.95 8.697
WisdomTree Germany Equity UCITS ETF - USD Hedged 27/12/2018 IE00BYQCZ682 17536 USD 272,287.97 15.5274
WisdomTree Global Quality Dividend Growth UCITS ETF - USD 27/12/2018 IE00BZ56RN96 63688 USD 1,169,279.43 18.3595
WisdomTree Global Quality Dividend Growth UCITS ETF - USD Acc 27/12/2018 IE00BZ56SW52 579761 USD 11,050,440.25 19.0603
WisdomTree India Quality UCITS ETF - USD 27/12/2018 IE00BDGSNK96 152500 USD 2,640,421.77 17.3142
WisdomTree India Quality UCITS ETF - USD Acc 27/12/2018 IE00BDGSNL04 222500 USD 3,860,987.63 17.3528
WisdomTree ISEQ 20 UCITS ETF 27/12/2018 IE00BVFB1H83 1300000 EUR 14,099,710.88 10.8459
WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc 27/12/2018 IE00BYQCZL35 210445 CHF 3,419,699.52 16.2498
WisdomTree Japan Equity UCITS ETF - EUR Hedged Acc 27/12/2018 IE00BYQCZJ13 818839 EUR 11,447,958.56 13.9807
WisdomTree Japan Equity UCITS ETF - GBP Hedged 27/12/2018 IE00BYQCZF74 104978 GBP 983,770.70 9.3712
WisdomTree Japan Equity UCITS ETF - JPY Acc 27/12/2018 IE00BYQCZN58 2183721 USD 37,172,825.41 17.0227
WisdomTree Japan Equity UCITS ETF - USD Hedged 27/12/2018 IE00BVXC4854 13310410 USD 189,175,767.80 14.2126
WisdomTree Japan Equity UCITS ETF - USD Hedged Acc 27/12/2018 IE00BYQCZD50 717932 USD 11,112,822.03 15.4789
WisdomTree Japan SmallCap Dividend UCITS ETF - USD 27/12/2018 IE00BFXYK923 20000 USD 864,702.54 43.2351
WisdomTree Japan SmallCap Dividend UCITS ETF - USD Acc 27/12/2018 IE00BFXYKD63 20000 USD 864,702.57 43.2351
WisdomTree UK Equity Income UCITS ETF 27/12/2018 IE00BYPGTJ26 840000 GBP 4,047,892.85 4.8189
WisdomTree US Equity Income UCITS ETF 27/12/2018 IE00BQZJBQ63 1508163 USD 26,658,688.96 17.6763
WisdomTree US Equity Income UCITS ETF - EUR Hedged Acc 27/12/2018 IE00BD6RZW23 23573 EUR 354,661.62 15.0452
WisdomTree US Equity Income UCITS ETF - GBP Hedged Acc 27/12/2018 IE00BD6RZZ53 169189 GBP 2,287,208.16 13.5187
WisdomTree US Equity Income UCITS ETF Acc 27/12/2018 IE00BD6RZT93 270041 USD 4,700,930.00 17.4082
WisdomTree US Multifactor UCITS ETF – USD 27/12/2018 IE00BD8ZCY59 10000 USD 441,518.50 44.1519
WisdomTree US Multifactor UCITS ETF – USD Acc 27/12/2018 IE00BD8ZD313 10000 USD 441,518.50 44.1519
WisdomTree US Quality Dividend Growth UCITS ETF - USD 27/12/2018 IE00BZ56RD98 33491 USD 654,450.48 19.5411
WisdomTree US Quality Dividend Growth UCITS ETF - USD Acc 27/12/2018 IE00BZ56RG20 696249 USD 14,055,253.36 20.1871
WisdomTree US Small Cap Dividend UCITS ETF 27/12/2018 IE00BQZJBT94 585000 USD 10,150,518.46 17.3513 Reported by GlobeNewswire 32 minutes ago.
* * * *
Fund Dealing Date ISIN Code Shares Base Net Assets NAV/Share
in Issue Currency
WisdomTree Artificial Intelligence UCITS ETF - USD Acc 27/12/2018 IE00BDVPNG13 40000 USD 910,745.18 22.7686
WisdomTree AT1 CoCo Bond UCITS ETF – USD 27/12/2018 IE00BZ0XVF52 290054 USD 26,907,309.00 92.7666
WisdomTree AT1 CoCo Bond UCITS ETF – EUR Hedged 27/12/2018 IE00BFNNN236 20828 EUR 2,011,849.41 96.5935
WisdomTree AT1 CoCo Bond UCITS ETF – GBP Hedged 27/12/2018 IE00BFNNN459 20740 GBP 2,013,541.98 97.085
WisdomTree AT1 CoCo Bond UCITS ETF – USD Acc 27/12/2018 IE00BZ0XVG69 7000 USD 652,259.97 93.18
WisdomTree AT1 CoCo Bond UCITS ETF – USD Hedged 27/12/2018 IE00BFNNN012 20962 USD 2,047,864.36 97.6941
WisdomTree CBOE S&P 500 PutWrite UCITS ETF - USD Acc 27/12/2018 IE00BD49R243 1630000 USD 74,633,063.57 45.7872
WisdomTree Emerging Asia Equity Income UCITS ETF 27/12/2018 IE00BYPGT035 1125000 USD 11,765,433.70 10.4582
WisdomTree Emerging Markets Equity Income UCITS ETF 27/12/2018 IE00BQQ3Q067 1792097 USD 25,939,217.53 14.4742
WisdomTree Emerging Markets Equity Income UCITS ETF Acc 27/12/2018 IE00BDF12W49 108242 USD 1,980,193.33 18.2941
WisdomTree Emerging Markets Small Cap Dividend UCITS ETF 27/12/2018 IE00BQZJBM26 1500000 USD 23,493,917.43 15.6626
WisdomTree Enhanced Commodity UCITS ETF – EUR Hedged Acc 27/12/2018 IE00BG88WG77 25000 EUR 231,753.89 9.2702
WisdomTree Enhanced Commodity UCITS ETF – GBP Hedged Acc 27/12/2018 IE00BG88WH84 1425000 GBP 13,266,277.11 9.3097
WisdomTree Enhanced Commodity UCITS ETF - USD 27/12/2018 IE00BZ1GHD37 475000 USD 4,670,919.51 9.8335
WisdomTree Enhanced Commodity UCITS ETF - USD Acc 27/12/2018 IE00BYMLZY74 22575000 USD 222,961,539.52 9.8765
WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR 27/12/2018 IE00BD49R912 30000 EUR 1,495,464.10 49.8488
WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR Acc 27/12/2018 IE00BD49RB39 30000 EUR 1,495,465.38 49.8488
WisdomTree EUR Government Bond Enhanced Yield UCITS ETF 27/12/2018 IE00BD49RJ15 30000 EUR 1,508,868.96 50.2956
WisdomTree EUR Government Bond Enhanced Yield UCITS ETF – EUR Acc 27/12/2018 IE00BD49RK20 30000 EUR 1,508,869.58 50.2957
WisdomTree Europe Equity Income UCITS ETF 27/12/2018 IE00BQZJBX31 3632471 EUR 41,807,175.13 11.5093
WisdomTree Europe Equity Income UCITS ETF Acc 27/12/2018 IE00BDF16007 40998 EUR 538,820.98 13.1426
WisdomTree Europe Equity UCITS ETF - CHF Hedged Acc 27/12/2018 IE00BYQCZT11 17096 CHF 246,471.31 14.4169
WisdomTree Europe Equity UCITS ETF - EUR Acc 27/12/2018 IE00BYQCZX56 540306 EUR 7,913,980.65 14.6472
WisdomTree Europe Equity UCITS ETF - GBP Hedged 27/12/2018 IE00BYQCZQ89 342454 GBP 3,294,376.42 9.6199
WisdomTree Europe Equity UCITS ETF - USD Hedged 27/12/2018 IE00BVXBH163 2668352 USD 40,749,156.80 15.2713
WisdomTree Europe Equity UCITS ETF - USD Hedged Acc 27/12/2018 IE00BYQCZP72 4249312 USD 73,160,282.15 17.217
WisdomTree Europe Small Cap Dividend UCITS ETF 27/12/2018 IE00BQZJC527 3230006 EUR 45,877,317.99 14.2035
WisdomTree Europe Small Cap Dividend UCITS ETF Acc 27/12/2018 IE00BDF16114 702168 EUR 8,653,092.61 12.3234
WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR 27/12/2018 IE00BZ56SY76 333881 EUR 4,193,658.43 12.5603
WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR Acc 27/12/2018 IE00BZ56TQ67 938013 EUR 13,016,350.80 13.8765
WisdomTree Germany Equity UCITS ETF - CHF Hedged Acc 27/12/2018 IE00BYQCZ914 45884 CHF 714,785.43 15.5781
WisdomTree Germany Equity UCITS ETF - EUR Acc 27/12/2018 IE00BYQCZC44 251123 EUR 3,484,112.35 13.8741
WisdomTree Germany Equity UCITS ETF - GBP Hedged 27/12/2018 IE00BVXBGY20 507894 GBP 4,417,130.95 8.697
WisdomTree Germany Equity UCITS ETF - USD Hedged 27/12/2018 IE00BYQCZ682 17536 USD 272,287.97 15.5274
WisdomTree Global Quality Dividend Growth UCITS ETF - USD 27/12/2018 IE00BZ56RN96 63688 USD 1,169,279.43 18.3595
WisdomTree Global Quality Dividend Growth UCITS ETF - USD Acc 27/12/2018 IE00BZ56SW52 579761 USD 11,050,440.25 19.0603
WisdomTree India Quality UCITS ETF - USD 27/12/2018 IE00BDGSNK96 152500 USD 2,640,421.77 17.3142
WisdomTree India Quality UCITS ETF - USD Acc 27/12/2018 IE00BDGSNL04 222500 USD 3,860,987.63 17.3528
WisdomTree ISEQ 20 UCITS ETF 27/12/2018 IE00BVFB1H83 1300000 EUR 14,099,710.88 10.8459
WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc 27/12/2018 IE00BYQCZL35 210445 CHF 3,419,699.52 16.2498
WisdomTree Japan Equity UCITS ETF - EUR Hedged Acc 27/12/2018 IE00BYQCZJ13 818839 EUR 11,447,958.56 13.9807
WisdomTree Japan Equity UCITS ETF - GBP Hedged 27/12/2018 IE00BYQCZF74 104978 GBP 983,770.70 9.3712
WisdomTree Japan Equity UCITS ETF - JPY Acc 27/12/2018 IE00BYQCZN58 2183721 USD 37,172,825.41 17.0227
WisdomTree Japan Equity UCITS ETF - USD Hedged 27/12/2018 IE00BVXC4854 13310410 USD 189,175,767.80 14.2126
WisdomTree Japan Equity UCITS ETF - USD Hedged Acc 27/12/2018 IE00BYQCZD50 717932 USD 11,112,822.03 15.4789
WisdomTree Japan SmallCap Dividend UCITS ETF - USD 27/12/2018 IE00BFXYK923 20000 USD 864,702.54 43.2351
WisdomTree Japan SmallCap Dividend UCITS ETF - USD Acc 27/12/2018 IE00BFXYKD63 20000 USD 864,702.57 43.2351
WisdomTree UK Equity Income UCITS ETF 27/12/2018 IE00BYPGTJ26 840000 GBP 4,047,892.85 4.8189
WisdomTree US Equity Income UCITS ETF 27/12/2018 IE00BQZJBQ63 1508163 USD 26,658,688.96 17.6763
WisdomTree US Equity Income UCITS ETF - EUR Hedged Acc 27/12/2018 IE00BD6RZW23 23573 EUR 354,661.62 15.0452
WisdomTree US Equity Income UCITS ETF - GBP Hedged Acc 27/12/2018 IE00BD6RZZ53 169189 GBP 2,287,208.16 13.5187
WisdomTree US Equity Income UCITS ETF Acc 27/12/2018 IE00BD6RZT93 270041 USD 4,700,930.00 17.4082
WisdomTree US Multifactor UCITS ETF – USD 27/12/2018 IE00BD8ZCY59 10000 USD 441,518.50 44.1519
WisdomTree US Multifactor UCITS ETF – USD Acc 27/12/2018 IE00BD8ZD313 10000 USD 441,518.50 44.1519
WisdomTree US Quality Dividend Growth UCITS ETF - USD 27/12/2018 IE00BZ56RD98 33491 USD 654,450.48 19.5411
WisdomTree US Quality Dividend Growth UCITS ETF - USD Acc 27/12/2018 IE00BZ56RG20 696249 USD 14,055,253.36 20.1871
WisdomTree US Small Cap Dividend UCITS ETF 27/12/2018 IE00BQZJBT94 585000 USD 10,150,518.46 17.3513 Reported by GlobeNewswire 32 minutes ago.
↧
↧
Council expresses interest in buying historic village estate
It is the only place in Europe that still operates open field farming
Reported by Lincolnshire Echo 1 day ago.
↧
BlackRock Greater Europe Investment Trust Plc - Net Asset Value(s)
NET ASSET VALUE BLACKROCK GREATER EUROPE INVESTMENT TRUST PLC 5493003R8FJ6I76ZUW55 The unaudited net asset values for BlackRock Greater Europe Investment Trust plc at close of business on 24 December 2018 were: 317.36p Capital only (undiluted) 317.36p Capital only (Diluted for...
Reported by PR Newswire 1 day ago.
↧
Met Police chief warns no-deal Brexit could put public safety at risk
Metropolitan Police Commissioner Cressida Dick said she hopes police will have 'as much as possible' to Europe-wide database access, as quickly as possible after Brexit.
Reported by MailOnline 20 hours ago.
↧
More Pages to Explore .....
